Pankaj Bhargava, MPM executive partner

Pankaj Bhar­ga­va was a cen­tral fig­ure in the group fash­ion­ing Gilead’s on­col­o­gy strat­e­gy. Now he’s jumped to the VC side and the next-gen game at Dana-Far­ber

Over the past 3 years, Pankaj Bhar­ga­va played a key role at Gilead as ther­a­peu­tics area head of on­col­o­gy, which put him in the dead cen­ter of one of the busiest pipeline makeovers in the in­dus­try.

“When I joined (the big biotech), there was a clear re­al­iza­tion that Gilead had missed the first boat with im­muno-on­col­o­gy,” he tells me. “We hadn’t gone in­to the PD-1s, the check­points, etc. They had just bought Kite and the ques­tion was how do we get in­to on­col­o­gy.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.